Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study to Test Different Doses of BI 456906 in Patients With Obesity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03591718
Recruitment Status : Completed
First Posted : July 19, 2018
Last Update Posted : March 22, 2021
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Main objective is to investigate the tolerability of different titration schemes of BI 456906 in otherwise healthy patients with obesity/overweight, and to determine a titration scheme for future studies.

Condition or disease Intervention/treatment Phase
Obesity Drug: BI 456906 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 131 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase I, Blinded Within Dose Groups, Multiple Dose, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Different Titration Schemes of BI 456906 in Patients With Obesity and Overweight.
Actual Study Start Date : July 26, 2018
Actual Primary Completion Date : April 20, 2020
Actual Study Completion Date : April 30, 2020

Arm Intervention/treatment
Experimental: BI 456906 Drug: BI 456906
Solution for injection

Experimental: Placebo Drug: Placebo
solution for injection

Primary Outcome Measures :
  1. Cumulative number [N (%)] of patients withdrawn from up-titration by up-titration scheme [ Time Frame: Up to 132 days ]

Secondary Outcome Measures :
  1. AUC0-168 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 168h) [ Time Frame: Up to 168 hours ]
  2. Cmax (maximum measured concentration of the analyte in plasma) after first dose [ Time Frame: Up to 132 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female patients ≥ 18 years and < 70 years of age at screening
  • Body Mass Index (BMI) ≥ 27 kg/m2 and <40 kg/m2 at screening
  • A minimum absolute body weight of 70 kg at screening and a stable body weight (defined as no more than 5% change) 3 months prior to screening
  • HbA1c <6.5%
  • Further inclusion criteria apply

Exclusion Criteria:

  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial
  • Supine blood pressure (BP) ≥160/100 mmHg at screening
  • Major surgery (major according to the investigator's assessment) performed within 12 weeks prior to randomization or planned within 12 months after screening
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Further exclusion criteria apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03591718

Layout table for location information
Profil Mainz GmbH & Co. KG
Mainz, Germany, 55116
Profil Institut für Stoffwechselforschung GmbH
Neuss, Germany, 41460
Sponsors and Collaborators
Boehringer Ingelheim
Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT03591718    
Other Study ID Numbers: 1404-0003
2018-000250-22 ( EudraCT Number )
First Posted: July 19, 2018    Key Record Dates
Last Update Posted: March 22, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. Studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. Studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). Requestors can use the following link http:// to: 1.find information in order to request access to clinical study data, for listed studies. 2.request access to clinical study documents that meet criteria, and upon a signed 'Document Sharing Agreement'.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Nutrition Disorders
Body Weight